Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06656351 · ClinicalTrials.gov registry record · Phase 2
B-FREE Chronic Babesiosis Study
A Phase 2 study of Chronic Babesiosis, sponsored by 60 Degrees Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06656351 is a Phase 2 study of Chronic Babesiosis that is actively recruiting participants, run by 60 Degrees Pharmaceuticals. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06656351, a Phase 2 study of Chronic Babesiosis, is actively recruiting participants, sponsored by 60 Degrees Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
Conditions Studied
Interventions
- DRUG Tafenoquine 100mg
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06656351
The ClinicalTrials.gov registry entry for NCT06656351 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 60 Degrees Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Babesiosis appearing as the primary indexed condition, and to 1 intervention - of which Tafenoquine 100mg is the first listed.
NCT06656351 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06656351 about?
NCT06656351 is a clinical study titled "B-FREE Chronic Babesiosis Study". Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
What is the current status of trial NCT06656351?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-11-18. Estimated completion is 2027-09.
What conditions does trial NCT06656351 study?
This clinical trial studies the following conditions: Chronic Babesiosis.
What interventions are being tested in trial NCT06656351?
The interventions under investigation include: Tafenoquine 100mg (DRUG).
Who is sponsoring clinical trial NCT06656351?
This trial is sponsored by 60 Degrees Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06656351 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.